High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern

Vista sencilla de ítem
dc.contributor.authorMoreira-Soto, Andres
dc.contributor.authorArguedas, Mauricio
dc.contributor.authorBrenes, Hebleen
dc.contributor.authorBuján, Willem
dc.contributor.authorCorrales-Aguilar, Eugenia
dc.contributor.authorDíaz, Cecilia
dc.contributor.authorEcheverri, Ann
dc.contributor.authorFlores-Díaz, Marietta
dc.contributor.authorGómez, Aarón
dc.contributor.authorHernández, Andrés
dc.contributor.authorHerrera, María
dc.contributor.authorLeón, Guillermo
dc.contributor.authorMacaya, Román
dc.contributor.authorKühne, Arne
dc.contributor.authorMolina-Mora, José Arturo
dc.contributor.authorMora, Javier
dc.contributor.authorSanabria, Alfredo
dc.contributor.authorSánchez, Andrés
dc.contributor.authorSánchez, Laura
dc.contributor.authorSegura, Álvaro
dc.contributor.authorSegura, Eduardo
dc.contributor.authorSolano, Daniela
dc.contributor.authorSoto, Claudio
dc.contributor.authorStynoski, Jennifer L
dc.contributor.authorVargas, Mariángela
dc.contributor.authorVillalta, Mauren
dc.contributor.authorReusken, Chantal, B. E. M
dc.contributor.authorDrosten, Christian
dc.contributor.authorGutiérrez, José María
dc.contributor.authorAlape-Girón, Alberto
dc.contributor.authorDrexler, Jan Felix
dc.date.accessioned2025-07-09T20:43:44Z
dc.date.available2025-07-09T20:43:44Z
dc.date.issued2022
dc.descriptionARTICULO
dc.description.abstractSARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146–1.078μg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment
dc.description.sponsorshipLos autores
dc.identifier.otherdoi: 10.3389/fmed.2021.735853
dc.identifier.urihttp://hdl.handle.net/20.500.11764/4906
dc.language.isoen
dc.publisherlos autores
dc.relation.ispartofseriesFrontiers in Medicine; v. 8 set. 2021: Article 735853
dc.subjectCOVID-19
dc.subjectANTICUERPOS EQUINOS
dc.titleHigh Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern
dc.typeArticle

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
20 fmed-08-735853.pdf
Tamaño:
344.07 KB
Formato:
Adobe Portable Document Format
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
85 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Investigaciones en la CCSS